Spots Global Cancer Trial Database for inc280
Every month we try and update this database with for inc280 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Study of INC280 in Patients With c-MET Dependent Advanced Solid Tumors | NCT01324479 | Solid Tumors | INC280 | 18 Years - | Novartis | |
| A Phase II, Open Label, Multiple Arm Study of AUY922, BYL719, INC280, LDK378 and MEK162 in Chinese Patients With Advanced Non-small Cell Lung Cancer | NCT02276027 | Adenocarcinoma ... | BYL719 INC280 LDK378 MEK162 | 18 Years - | Novartis | |
| A Phase 2 Study of the MET Kinase Inhibitor INC280 in Papillary Renal Cell Cancer | NCT02019693 | Kidney Cancer | INC280 | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Study of Capmatinib Efficacy in Comparison With Docetaxel in Previously Treated Participants With Non-small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation | NCT04427072 | Carcinoma, Non-... | Capmatinib Docetaxel | 18 Years - | Novartis | |
| Safety and Efficacy of INC280 and Buparlisib (BKM120) in Patients With Recurrent Glioblastoma | NCT01870726 | c-MET Inhibitor... | INC280 Buparlisib | 18 Years - | Novartis | |
| A Dose Escalation Study to Assess PK, Safety and Tolerability of INC280 When Taken With Food in cMET Dysregulated Advanced Solid Tumors. | NCT02925104 | cMET Dysegulati... | INC280 | 18 Years - | Novartis | |
| Study of Capmatinib Efficacy in Comparison With Docetaxel in Previously Treated Participants With Non-small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation | NCT04427072 | Carcinoma, Non-... | Capmatinib Docetaxel | 18 Years - | Novartis | |
| Study of Capmatinib Efficacy in Comparison With Docetaxel in Previously Treated Participants With Non-small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation | NCT04427072 | Carcinoma, Non-... | Capmatinib Docetaxel | 18 Years - | Novartis | |
| Study of Capmatinib in Chinese Adult Patients With Advanced Non-small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation | NCT04677595 | Non-Small Cell ... | Capmatinib | 18 Years - | Novartis | |
| LGX818 and MEK162 in Combination With a Third Agent (BKM120, LEE011, BGJ398 or INC280) in Advanced BRAF Melanoma | NCT02159066 | Melanoma | LGX818 MEK162 LEE011 BGJ398 BKM120 INC280 | 18 Years - | Pfizer | |
| Study of Efficacy and Safety of Novel Spartalizumab Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma | NCT03484923 | Melanoma | PDR001 LAG525 INC280 ACZ885 LEE011 | 18 Years - | Novartis | |
| A Phase 2 Study of the MET Kinase Inhibitor INC280 in Papillary Renal Cell Cancer | NCT02019693 | Kidney Cancer | INC280 | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| INC280 in Healthy Subjects With Impaired Hepatic Function and Subjects With Normal Hepatic Function | NCT02474537 | Hepatic Impairm... | INC280 | 18 Years - 75 Years | Novartis | |
| Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLC | NCT03333343 | EGFR-mutant Non... | EGF816 trametinib ribociclib LXH254 INC280 gefitinib | 18 Years - | Novartis | |
| Study of Safety and Efficacy of EGFR-TKI EGF816 in Combination With cMET Inhibitor INC280 in Adult Patients With EGFR Mutated Non Small Cell Lung Cancer. | NCT02335944 | Non Small Cell ... | Capmatinib Nazartinib | 18 Years - | Novartis | |
| Study of Capmatinib in Chinese Adult Patients With Advanced Non-small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation | NCT04677595 | Non-Small Cell ... | Capmatinib | 18 Years - | Novartis | |
| Study of Efficacy and Safety of Nivolumab in Combination With EGF816 and of Nivolumab in Combination With INC280 in Patients With Previously Treated Non-small Cell Lung Cancer | NCT02323126 | Non Small Cell ... | EGF816 INC280 Nivolumab | 18 Years - | Novartis | |
| Study of Efficacy and Safety of Novel Spartalizumab Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma | NCT03484923 | Melanoma | PDR001 LAG525 INC280 ACZ885 LEE011 | 18 Years - | Novartis | |
| A Dose Escalation Study to Assess PK, Safety and Tolerability of INC280 When Taken With Food in cMET Dysregulated Advanced Solid Tumors. | NCT02925104 | cMET Dysegulati... | INC280 | 18 Years - | Novartis | |
| Study of Capmatinib and Spartalizumab Combination Therapy vs Docetaxel in Non-small Cell Lung Cancer | NCT03647488 | Carcinoma, Non-... | Capmatinib Spartalizumab Docetaxel | 18 Years - | Novartis | |
| Study of Safety and Efficacy of EGFR-TKI EGF816 in Combination With cMET Inhibitor INC280 in Adult Patients With EGFR Mutated Non Small Cell Lung Cancer. | NCT02335944 | Non Small Cell ... | Capmatinib Nazartinib | 18 Years - | Novartis | |
| Study of INC280 in Patients With c-MET Dependent Advanced Solid Tumors | NCT01324479 | Solid Tumors | INC280 | 18 Years - | Novartis | |
| Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLC | NCT03333343 | EGFR-mutant Non... | EGF816 trametinib ribociclib LXH254 INC280 gefitinib | 18 Years - | Novartis | |
| Study of Efficacy and Safety of Nivolumab in Combination With EGF816 and of Nivolumab in Combination With INC280 in Patients With Previously Treated Non-small Cell Lung Cancer | NCT02323126 | Non Small Cell ... | EGF816 INC280 Nivolumab | 18 Years - | Novartis | |
| A Dose Escalation Study to Assess PK, Safety and Tolerability of INC280 When Taken With Food in cMET Dysregulated Advanced Solid Tumors. | NCT02925104 | cMET Dysegulati... | INC280 | 18 Years - | Novartis | |
| A Phase I Study of INC280 in Japanese Patients With Advanced Solid Tumors | NCT01546428 | Advanced Solid ... | INC280 | 18 Years - | Novartis | |
| Study of Efficacy and Safety INC280 in Patients With Advanced Hepatocellular Carcinoma | NCT01964235 | Advanced Hepato... | INC280 Placebo | 18 Years - | Novartis | |
| Study Efficacy and Safety of INC280 in Patients With Advanced Hepatocellular Carcinoma. | NCT01737827 | Advanced Hepato... | INC280 | 18 Years - | Novartis | |
| Phase II of Neoadjuvant and Adjuvant Capmatinib in NSCLC | NCT04926831 | Non-small Cell ... | capmatinib | 18 Years - 90 Years | Novartis | |
| A DDI Study to Assess the Effect of INC280 on the PK of Midazolam and Caffeine in Patients With cMET-dysregulated Advanced Solid Tumors | NCT02520752 | cMET-dysregulat... | INC280 Midazolam Caffeine | 18 Years - | Novartis | |
| Study of Efficacy and Safety INC280 in Patients With Advanced Hepatocellular Carcinoma | NCT01964235 | Advanced Hepato... | INC280 Placebo | 18 Years - | Novartis | |
| A Drug-drug Interaction (DDI) Study to Assess the Effect of INC280 on the Pharmacokinetics of Digoxin and Rosuvastatin in Patients With cMET-dysregulated Advanced Solid Tumors | NCT02626234 | cMET-dysregulat... | INC280 digoxin rosuvastatin | 18 Years - | Novartis | |
| Study to Allow Patients Previously Participating in a Novartis Sponsored Trial to Continue Receiving Capmatinib Treatment as Single Agent or in Combination With Other Treatments or the Combination Treatment Alone | NCT03040973 | Advanced Solid ... | Capmatinib Nazartinib Gefitinib Osimertinib | 18 Years - | Novartis | |
| Study of Efficacy and Safety of Nivolumab in Combination With EGF816 and of Nivolumab in Combination With INC280 in Patients With Previously Treated Non-small Cell Lung Cancer | NCT02323126 | Non Small Cell ... | EGF816 INC280 Nivolumab | 18 Years - | Novartis | |
| INC280 Combined With Bevacizumab in Patients With Glioblastoma Multiforme | NCT02386826 | Glioblastoma Mu... Gliosarcoma Colorectal Canc... Renal Cell Carc... | INC280 bevacizumab | 18 Years - | SCRI Development Innovations, LLC | |
| A Safety and Efficacy Study of INC280 and Gefitinib in Patients With EGFR Mutated, c-MET-amplified NSCLC Who Have Progressed After EGFRi Treatment | NCT01610336 | Non-small Cell ... | INC280 Gefitinib | 18 Years - | Novartis | |
| A Safety and Efficacy Study of INC280 and Gefitinib in Patients With EGFR Mutated, c-MET-amplified NSCLC Who Have Progressed After EGFRi Treatment | NCT01610336 | Non-small Cell ... | INC280 Gefitinib | 18 Years - | Novartis | |
| INC280 and Erlotinib Hydrochloride in Treating Patients With Non-small Cell Lung Cancer | NCT01911507 | Recurrent Non-s... | INC280 erlotinib hydro... | 18 Years - | University of California, Davis |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
